Mumbai, January 19, 2018: Panacea Biotec has signed two long term agreements with Serum Institute of India (SII) and SII’s wholly owned subsidiary, Bilthovan Biologicals B.
Under the collaboration, SII is entitled to manufacture and sell fully liquid whole cell pertussis (wP) and salk based injectable polio vaccine (IPV) based hexavalent vaccine developed and commercialised by Panacea Biotec, a first of its king in this category.
Under the collaboration, Serum Institute of India will ensure supply of IPV bulk to Panacea Biotech, an important constituent of the Hexavalent vaccine, from its wholly owned subsidiary BBIO, a bioengineering and pharmaceutical company, registered in the Netherlands having technology and expertise for making the IPV, earlier possessed by only 3 other vaccine manufacturers in the world.
United News of India
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…